Free Trial
ASX:ACR

Acrux (ACR) Stock Price, News & Analysis

Acrux logo

About Acrux Stock (ASX:ACR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
4,000 shs
Average Volume
N/A
Market Capitalization
$12.47 million
P/E Ratio
N/A
Dividend Yield
11.66%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Remove Ads
Receive ACR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter.

ACR Stock News Headlines

South African group buys Cononish gold mine
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Acrux Limited Announces Issuance of New Options
See More Headlines

ACR Stock Analysis - Frequently Asked Questions

Acrux Limited (ASX:ACR) issued its quarterly earnings data on Thursday, February, 21st. The company reported ($0.02) EPS for the quarter. Acrux had a negative net margin of 113.93% and a negative trailing twelve-month return on equity of 130.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acrux investors own include Altimmune (ALT), ANZ Group (ANZ), Lynas Rare Earths (LYC), MV Oil Trust (MVO), Organigram (OGI), BHP Group (BHP) and Beacon Roofing Supply (BECN).

Company Calendar

Last Earnings
2/21/2019
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Trading
Current Symbol
ASX:ACR
CIK
N/A
Fax
N/A
Employees
2,018
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,800,000.00
Net Margins
-113.93%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.09 million
Price / Cash Flow
1.57
Book Value
A$0.01 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$12.47 million
Optionable
Not Optionable
Beta
1.21
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (ASX:ACR) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners